Comparative Pharmacology
Head-to-head clinical analysis: ADALAT versus CLEVIPREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADALAT versus CLEVIPREX.
ADALAT vs CLEVIPREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
Cleviprex (clevidipine) is a dihydropyridine L-type calcium channel blocker with high vascular selectivity. It inhibits calcium influx into vascular smooth muscle cells, causing arterial vasodilation and reduced peripheral vascular resistance.
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
Initiate intravenous infusion at 1-2 mg/kg/hr, titrate by 0.5-1 mg/kg/hr every 90 minutes up to maximum 32 mg/kg/hr. Maintenance dose: 4-6 mg/kg/hr. Route: IV. Frequency: continuous infusion.
None Documented
None Documented
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
Terminal elimination half-life: 2.7 minutes (dihydropyridine ring reduction) and 15 minutes (ester hydrolysis); clinical context: rapid offset allows precise titration
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
Renal: 63–73% as metabolites, fecal: 7–10%, unchanged drug in urine: <1%
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker